– USA, CA – Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced the appointment of Brent Shafer and Dr. Tom Miller (Ph.D.) to its board of directors, effective immediately.
“We are thrilled to welcome Brent and Tom to our board,” said CEO Marc Stapley. “They are both seasoned business leaders with extensive healthcare industry experience who will further broaden our board’s mix of backgrounds and expertise.”
Brent Shafer will join the Compensation Committee while Dr. Miller will serve on the Regulatory and Compliance Committee.
About Brent Shafer
Brent Shafer brings over 40 years of experience across health information technologies, medical devices, and a variety of healthcare solutions to the company. He previously served as chairman and CEO of Cerner Corporation and CEO of Philips North America and Philips Home Healthcare Solutions. Before that, he served in a variety of roles at Hillrom, GE Medical Systems, and Johnson & Johnson.
“I am thrilled to join the Veracyte board to support the management team in advancing their vision,” said Brent Shafer. “I look forward to leveraging my experience to help accelerate the momentum underway at Veracyte with their focus on empowering physicians with the high-value insights they need to best serve patients.”
About Dr. Tom Miller
Dr. Tom Miller is a scientist and entrepreneur with a focus on the nexus of AI, chemistry, and biology. He co-founded and serves as CEO of Iambic Therapeutics, a biotechnology company that is disrupting the therapeutics landscape with an AI-driven, drug-discovery platform. Before that, he spent over 10 years as a tenured professor at Caltech, publishing more than 140 peer-reviewed articles and patents.
“It’s an honor to be a part of a company with such a compelling platform and that is so well-positioned to positively impact the journey of so many cancer patients,” said Dr. Tom Miller. “I am particularly excited by the company’s increased investment in AI as part of their focus on helping clinicians, researchers and patients gain even further ground on cancer.”
About Veracyte
Veracyte is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development.
For more: https://www.veracyte.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.